Johns Hopkins Diabetes Guide
PDE-5 inhibitors
INDICATIONS
FDA
FDA
- Treatment of erectile dysfunction (ED)
- Treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability and delay clinical worsening (Revatio and Adcirca)
- Treatment of benign prostatic hyperplasia (Cialis)
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: January 7, 2018
Citation
Crowder, Alona, and Ari S Eckman. "PDE-5 Inhibitors." Johns Hopkins Diabetes Guide, 2018. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547134/all/PDE_5_inhibitors.
Crowder A, Eckman AS. PDE-5 inhibitors. Johns Hopkins Diabetes Guide. 2018. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547134/all/PDE_5_inhibitors. Accessed June 7, 2023.
Crowder, A., & Eckman, A. S. (2018). PDE-5 inhibitors. In Johns Hopkins Diabetes Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547134/all/PDE_5_inhibitors
Crowder A, Eckman AS. PDE-5 Inhibitors [Internet]. In: Johns Hopkins Diabetes Guide. ; 2018. [cited 2023 June 07]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547134/all/PDE_5_inhibitors.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - PDE-5 inhibitors
ID - 547134
A1 - Crowder,Alona,PharmD
AU - Eckman,Ari,M.D.
Y1 - 2018/01/07/
BT - Johns Hopkins Diabetes Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547134/all/PDE_5_inhibitors
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
